A Truneh Selected Research

clenoliximab

2/2000

Inhibition of contact sensitivity in human CD4+ transgenic mice by human CD4-specific monoclonal antibodies: CD4+ T-cell depletion is not required.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A Truneh Research Topics

Disease

3	Neoplasms (Cancer) 12/2003 - 04/2000
1	Lymphoma (Lymphomas) 12/2003
1	Asthma (Bronchial Asthma) 11/2001
1	Infections 04/2000
1	Experimental Melanoma 04/2000
1	Contact Dermatitis (Eczema, Contact) 02/2000

Drug/Important Bio-Agent (IBA)

2	keliximabIBA 04/2000 - 02/2000
1	Member 14 Tumor Necrosis Factor ReceptorsIBA 12/2003
1	LigandsIBA 12/2003
1	Lymphotoxin-alpha (Lymphotoxin)IBA 12/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 12/2003
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 12/2003
1	CD40 Ligand (CD40L)IBA 12/2003
1	AntibodiesIBA 11/2001
1	Monoclonal AntibodiesIBA 02/2000
1	Interleukin-4 (Interleukin 4)IBA 02/2000
1	clenoliximabIBA 02/2000
1	HaptensIBA 02/2000
1	OxazoloneIBA 02/2000
1	Interferon-gamma (Interferon, gamma)IBA 02/2000

Therapy/Procedure

1	Drug Therapy (Chemotherapy) 12/2003
1	Immunotherapy 09/2001